BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 20467228)

  • 1. [Multiple myeloma complicated with Takotsubo cardiomyopathy].
    Mitsumori T; Nakajima K; Nozaki Y; Hamanaka S; Nagashima T; Kirito K; Iwao N; Komatsu N
    Rinsho Ketsueki; 2010 Apr; 51(4):291-6. PubMed ID: 20467228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperammonemia after high-dose chemotherapy and stem cell transplantation.
    Frere P; Canivet JL; Gennigens C; Rebeix JP; Fillet G; Beguin Y
    Bone Marrow Transplant; 2000 Aug; 26(3):343-5. PubMed ID: 10967577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Melphalan-prednisolone and vincristine-doxorubicin-dexamethasone chemotherapy followed by prednisolone/interferon maintenance therapy for multiple myeloma: Japan Clinical Oncology Group Study, JCOG0112.
    Chou T; Tobinai K; Uike N; Asakawa T; Saito I; Fukuda H; Mizoroki F; Ando K; Iida S; Ueda R; Tsukasaki K; Hotta T;
    Jpn J Clin Oncol; 2011 Apr; 41(4):586-9. PubMed ID: 21247967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Multiple myeloma of the IgD-lambda type invading CNS].
    Kitamura K; Takeuchi J; Kanbe E; Oka H; Saiki M; Aikawa S; Kura Y; Hatta Y; Yamazaki T; Ito T; Sawada U; Horie T
    Rinsho Ketsueki; 2004 Oct; 45(10):1124-8. PubMed ID: 15553049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Secondary myeloid/natural killer cell acute leukemia appeared in multiple myeloma treated with melphalan].
    Kaya H; Nakamura S; Yamazaki H; Kumabashiri I; Ohtake S; Matsuda T
    Rinsho Ketsueki; 1995 Jul; 36(7):682-6. PubMed ID: 7563597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Four cases of therapy-related leukemia in multiple myeloma].
    Natori K; Izumi H; Kaneko K; Ishihara S; Nagase D; Fujimoto Y; Kato M; Umeda M; Kuraishi Y
    Gan To Kagaku Ryoho; 2007 Jan; 34(1):121-4. PubMed ID: 17220686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High dose simvastatin does not reverse resistance to vincristine, adriamycin, and dexamethasone (VAD) in myeloma.
    van der Spek E; Bloem AC; Sinnige HA; Lokhorst HM
    Haematologica; 2007 Dec; 92(12):e130-1. PubMed ID: 18055977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Refractory multiple myeloma treated with homoharringtonine: report of two cases.
    Yang X; Yang C; Shao K; Ye X; Meng H; Zhou Y; Qian W
    Ann Hematol; 2007 Dec; 86(12):919-21. PubMed ID: 17641891
    [No Abstract]   [Full Text] [Related]  

  • 9. [Successful treatment of secondary erythroleukemia with androgen].
    Ogata K; Futaki M; Inokuchi K; Gomi S; Ohki I; Kuwabara T; Dan KZ; Kuriya S; Nomura T; Shinohara T
    Rinsho Ketsueki; 1989 Jul; 30(7):1079-83. PubMed ID: 2810794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol].
    Marisavljević D; Bosković D; Radosević N; Elezović I; Tomin D; Gotić M; Antunović P
    Srp Arh Celok Lek; 1996; 124(11-12):292-6. PubMed ID: 9132962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [New treatment strategies for multiple myeloma].
    Ozaki S
    Rinsho Ketsueki; 2009 Oct; 50(10):1506-17. PubMed ID: 19915360
    [No Abstract]   [Full Text] [Related]  

  • 12. Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT.
    Ahmad I; Islam T; Chanan-Khan A; Hahn T; Wentling D; Becker JL; McCarthy PL; Alam AR
    Bone Marrow Transplant; 2002 Apr; 29(7):577-80. PubMed ID: 11979306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients.
    Hussein MA; Wood L; Hsi E; Srkalovic G; Karam M; Elson P; Bukowski RM
    Cancer; 2002 Nov; 95(10):2160-8. PubMed ID: 12412170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: a Phase III multicenter randomized trial.
    Rifkin RM; Gregory SA; Mohrbacher A; Hussein MA
    Cancer; 2006 Feb; 106(4):848-58. PubMed ID: 16404741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of refractory multiple myeloma with vincristine, adriamycin, dexamethasone, and with repeated application of cyclophosphamide (C-VAD).
    Adam Z; Elbl L; Vorlicek J; Hájek R; Hájek D; Hejlová N; Králová E; Novotná H
    Acta Med Austriaca; 1994; 21(4):111-5. PubMed ID: 7871966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The VAD-DCEP sequence is an effective pre-transplant therapy in untreated multiple myeloma.
    Corso A; Barbarano L; Zappasodi P; Cairoli R; Alessandrino EP; Mangiacavalli S; Ferrari D; Fava S; Fiumanò M; Frigerio G; Isa L; Luraschi A; Klersy C; De Paoli A; Vergani C; Banfi L; Perego D; Ucci G; Pinotti G; Savarè M; Uziel L; Vismara A; Morra E; Lazzarino M
    Haematologica; 2004 Sep; 89(9):1124-7. PubMed ID: 15377474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pneumonia caused by Salmonella in a patient with myeloma].
    Fernández P; Roldán V; García MC; Gil MT; Rivas C
    Sangre (Barc); 1995 Jun; 40(3):234-5. PubMed ID: 7570286
    [No Abstract]   [Full Text] [Related]  

  • 18. Acute leukemia of plasmablastic type as terminal phase of multiple myeloma.
    Piccinini L; Artusi T; Bonacorsi G; Arigliano V
    Haematologica; 2002 Feb; 87(2):EIM04. PubMed ID: 11836178
    [No Abstract]   [Full Text] [Related]  

  • 19. Melphalan-prednisone versus alternating combination VAD/MP or VND/MP as primary therapy for multiple myeloma: final analysis of a randomized clinical study.
    Cavo M; Benni M; Ronconi S; Fiacchini M; Gozzetti A; Zamagni E; Cellini C; Tosi P; Baccarani M; Tura S;
    Haematologica; 2002 Sep; 87(9):934-42. PubMed ID: 12217805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intensive chemotherapy with combinations containing anthracyclines for refractory and relapsing multiple myeloma. Finnish Leukaemia Group.
    Palva IP; Ahrenberg P; Ala Harja K; Almqvist A; Elonen E; Hallman H; Hänninen A; Ilvonen M; Isomaa B; Jouppila J
    Eur J Haematol; 1990 Feb; 44(2):121-4. PubMed ID: 2180741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.